{"content":"<li class=\"n-box-item date-title\" data-end=\"1490759999\" data-start=\"1490673600\" data-txt=\"Sunday, December 22, 2019\">Tuesday, March 28, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3254020\" data-ts=\"1490739497\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRTX\" target=\"_blank\">VRTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254020-vertex-pharma-to-seek-approval-of-new-cystic-fibrosis-drug\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vertex Pharma to seek approval of new cystic fibrosis drug</a></h4><ul>     <li>Vertex Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a>) <font color='green'>+6.3%</font>&nbsp;AH after saying it would <a href=\"http://www.marketwatch.com/story/vertex-to-seek-approval-of-new-cystic-fibrosis-drug-2017-03-28\" target=\"_blank\">apply for regulatory approval</a> in the U.S. and European Union for an experimental cystic fibrosis drug after the treatment significantly improved  lung function in late-stage trials.</li><li>The drug is  intended to treat patients who have one or two copies of a genetic  mutation that is the most common cause of cystic fibrosis, a progressive  lung disease that affects ~30K people in the U.S.</li><li>If approved, the new drug would present patients with an alternative to the company's drug Orkambi, which can cause chest tightness and other side effects that have led to disappointing sales.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3254020\" data-linked=\"Vertex Pharma to seek approval of new cystic fibrosis drug\" data-tweet=\"$VRTX - Vertex Pharma to seek approval of new cystic fibrosis drug https://seekingalpha.com/news/3254020-vertex-pharma-to-seek-approval-of-new-cystic-fibrosis-drug?source=tweet\" data-url=\"https://seekingalpha.com/news/3254020-vertex-pharma-to-seek-approval-of-new-cystic-fibrosis-drug\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254019\" data-ts=\"1490738537\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RH\" target=\"_blank\">RH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254019-rh-jumps-15_9-on-q4-beat-robust-revenue-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RH jumps 15.9% on Q4 beat, robust revenue guidance</a></h4><ul>   <li>Restoration Hardware parent RH (<a href=\"http://seekingalpha.com/symbol/RH\" target=\"_blank\">RH</a> <font color='green'>+3.6%</font>) is <font color='green'>up 15.9%</font> after hours after reporting <a href=\"https://seekingalpha.com/news/3253972-rh-beats-0_03-beats-revenue\" target=\"_blank\">Q4 earnings</a> where revenues declined less than expected and the company forecast robust growth ahead.</li>    <li>\"We are now through the most uncertain stages of our transformation,\" says CEO Gary Friedman, who said a temporary depression in financial results will strengthen the brand ahead.</li>    <li>While adjusted net revenues fell 9%, comparable brand revenues were down 18%. Adjusted net income fell to $27.9M from a year-ago $41.2M.</li>    <li>The company's guiding to Q1 revenue growth of 16-20% ($530M-$545M, well above consensus for $485M), with 5 points coming from accelerated inventory optimization and another 5 from the acquisition of Waterworks. The revenue boost will have a negative effective on margins and earnings, it says, forecasting net income of $0.8M-$2.4M (EPS of $0.02-$0.06 vs. consensus for $0.05).</li>    <li>For the full year it sees revenues of $2.3B-$2.4B (8-12% growth, and vs. consensus for $2.32B) and EPS of $1.78-$2.19 vs. an expected $1.94.</li>    <li><a href=\"https://seekingalpha.com/pr/16783553-rh-reports-fourth-quarter-fiscal-2016-financial-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3254019\" data-linked=\"RH jumps 15.9% on Q4 beat, robust revenue guidance\" data-tweet=\"$RH - RH jumps 15.9% on Q4 beat, robust revenue guidance https://seekingalpha.com/news/3254019-rh-jumps-15_9-on-q4-beat-robust-revenue-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3254019-rh-jumps-15_9-on-q4-beat-robust-revenue-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254013\" data-ts=\"1490737053\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254013-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/RH' title='RH'>RH</a> <font color='green'>+17.8%</font>. <a href='https://seekingalpha.com/symbol/VRNT' title='Verint Systems Inc.'>VRNT</a> <font color='green'>+8.2%</font>. <a href='https://seekingalpha.com/symbol/ITCI' title='Intra-Cellular Therapies Inc.'>ITCI</a> <font color='green'>+2.2%</font>. <a href='https://seekingalpha.com/symbol/WPX' title='WPX Energy, Inc.'>WPX</a> <font color='green'>+1.7%</font>. <a href='https://seekingalpha.com/symbol/AUPH' title='Aurinia Pharmaceuticals Inc.'>AUPH</a> <font color='green'>+1.7%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/PTX' title='Pernix Therapeutics Holdings, Inc.'>PTX</a> <font color='red'>-11.7%</font>. DEPO <font color='red'>-5.4%</font>. <a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a> <font color='red'>-4.2%</font>. <a href='https://seekingalpha.com/symbol/AVP' title='Avon Products, Inc.'>AVP</a> <font color='red'>-3.5%</font>. <a href='https://seekingalpha.com/symbol/SONC' title='Sonic Corp.'>SONC</a> <font color='red'>-2.4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3254013\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$RH $VRNT $ITCI - After Hours Gainers / Losers https://seekingalpha.com/news/3254013-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3254013-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254010\" data-ts=\"1490736632\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRWI\" target=\"_blank\">DRWI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254010-dragonwaveplus-26-after-knoxville-agency-win\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DragonWave +26% after Knoxville agency win</a></h4><ul>   <li>DragonWave (NASDAQ:<a href='https://seekingalpha.com/symbol/DRWI' title='DragonWave Inc.'>DRWI</a>) is again on the move (<font color='green'>up 25.9%</font> in postmarket trading) after touting a customer win.</li>    <li>The <a href=\"https://seekingalpha.com/pr/16783644-knoxville-utilities-board-selects-dragonwave-harmony-enhanced-mc-smart-grid-modernization\" target=\"_blank\">Knoxville Utilities Board</a> has chosen its Harmony Enhanced MC backhaul solution, the company says. The agency, independent of the city of Knoxville, Tenn., will use the radios to extend existing fiber/wireline facilities into a hybrid wireless/wireline network.</li>    <li>Shares have jumped after hours from time to time after customer contract wins, but YTD the stock is <font color='red'>down 48%</font>.</li><li>DragonWave plans an April 5 webinar to discuss the utility use case.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3254010\" data-linked=\"DragonWave +26% after Knoxville agency win\" data-tweet=\"$DRWI - DragonWave +26% after Knoxville agency win https://seekingalpha.com/news/3254010-dragonwaveplus-26-after-knoxville-agency-win?source=tweet\" data-url=\"https://seekingalpha.com/news/3254010-dragonwaveplus-26-after-knoxville-agency-win\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254005\" data-ts=\"1490735068\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATHX\" target=\"_blank\">ATHX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254005-william-blair-sees-athersys-nearly-10-bagger-sharesplus-16-in-post-market\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">William Blair sees Athersys as nearly a 10-bagger; shares +16% in post-market</a></h4><ul><li><a href=\"https://twitter.com/thenotablecalls\" target=\"_blank\">via Notable Calls</a></li><li>Athersys' (NASDAQ:<a href='https://seekingalpha.com/symbol/ATHX' title='Athersys, Inc.'>ATHX</a>) MultiStem is a potentially revolutionary stroke treatment, says William Blair, initiating coverage with an $11 price target - this vs. today's close of $1.18.</li><li>The team at Blair sees peak sales potential of $3.9B against the company's current market cap of just $133M.</li><li>Shares&nbsp;<font color='green'>+16.1%</font>&nbsp;after hours to $1.37.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254005\" data-linked=\"William Blair sees Athersys as nearly a 10-bagger; shares +16% in post-market\" data-tweet=\"$ATHX - William Blair sees Athersys as nearly a 10-bagger; shares +16% in post-market https://seekingalpha.com/news/3254005-william-blair-sees-athersys-nearly-10-bagger-sharesplus-16-in-post-market?source=tweet\" data-url=\"https://seekingalpha.com/news/3254005-william-blair-sees-athersys-nearly-10-bagger-sharesplus-16-in-post-market\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254003\" data-ts=\"1490734774\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTX\" target=\"_blank\">PTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254003-pernix-q4-top-line-down-35-operating-loss-widens-shares-off-9-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pernix Q4 top line down 35%, operating loss widens; shares off 9% after hours</a></h4><ul><li>Nano cap Pernix Therapeutics (NYSEMKT:<a href='https://seekingalpha.com/symbol/PTX' title='Pernix Therapeutics Holdings, Inc.'>PTX</a>) slips&nbsp;<font color='red'>9%</font>&nbsp;after hours on the heels of its <a href=\"https://seekingalpha.com/pr/16783532-pernix-therapeutics-announces-fourth-quarter-full-year-2016-financial-results\" target=\"_blank\">release </a>of Q4 and 2016 results. Q4 revenues were $30.1, down 35% from a year ago. EBITDA was ($53.9M) down from a loss of ($23.1). Treximet Q4 sales of $8.8M were down 67% and down 34% ($66.9M) for the year.</li><li>Net revenues of Treximet for the year were negatively impacted by $15.3 million of disputed rebate claims, which were recorded during 2016 for sales which occurred in prior periods ($12.5 million and $2.8 million for the years ended December 31, 2015 and 2014, respectively) related to the unfavorable arbitration ruling in its dispute with GlaxoSmithKline.</li></ul><div class=\"tiny-share-widget\" data-id=\"3254003\" data-linked=\"Pernix Q4 top line down 35%, operating loss widens; shares off 9% after hours\" data-tweet=\"$PTX $PTX-OLD - Pernix Q4 top line down 35%, operating loss widens; shares off 9% after hours https://seekingalpha.com/news/3254003-pernix-q4-top-line-down-35-operating-loss-widens-shares-off-9-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3254003-pernix-q4-top-line-down-35-operating-loss-widens-shares-off-9-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3254002\" data-ts=\"1490734630\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRNT\" target=\"_blank\">VRNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3254002-verint-systemsplus-7_5-q4-earnings-come-in-hot\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verint Systems +7.5% as Q4 earnings come in hot</a></h4><ul>   <li>Verint Systems (<a href=\"http://seekingalpha.com/symbol/VRNT\" target=\"_blank\">VRNT</a> <font color='red'>-1.1%</font>) has stepped <font color='green'>up 7.5%</font> after the bell after posting <a href=\"https://seekingalpha.com/news/3253971-verint-systems-beats-0_04-beats-revenue\" target=\"_blank\">Q4 earnings</a> that beat on top and bottom lines as revenues grew steadily in both key segments.</li>    <li>Operating income came to $19.4M ($72.4M on a non-GAAP basis) in what the company acknowledges is typically the year's strongest quarter.</li>    <li>Revenue breakout: Product, $124.3M (up 7.9%); Service and Support, $171.5M (up 3.6%). By segment (non-GAAP): Customer Engagement, $190.5M (up 6%); Cyber Intelligence, $109M (up 6.8%).</li>    <li>For the coming year, Verint is guiding to mid-single digit revenue growth in Customer Engagement, and high single digits in Cyber Intelligence, leading to forecasts of $1.14B in revenue plus or minus 2% (vs. consensus for $1.13B) and EPS at the midpoint of $2.70 (vs. consensus $2.71).</li>    <li><a href=\"https://seekingalpha.com/pr/16783551-verint-reports-fourth-quarter-full-year-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3254002\" data-linked=\"Verint Systems +7.5% as Q4 earnings come in hot\" data-tweet=\"$VRNT - Verint Systems +7.5% as Q4 earnings come in hot https://seekingalpha.com/news/3254002-verint-systemsplus-7_5-q4-earnings-come-in-hot?source=tweet\" data-url=\"https://seekingalpha.com/news/3254002-verint-systemsplus-7_5-q4-earnings-come-in-hot\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253996\" data-ts=\"1490733540\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALQA\" target=\"_blank\">ALQA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253996-alliqua-bio-readies-equity-offering-shares-slip-17-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alliqua Bio readies equity offering; shares slip 17% after hours</a></h4><ul><li>Thinly traded nano cap Alliqua BioMedical (NASDAQ:<a href='https://seekingalpha.com/symbol/ALQA' title='Alliqua BioMedical, Inc.'>ALQA</a>) is off&nbsp;<font color='red'>17%</font>&nbsp;after hours on average volume in response to its <a href=\"https://seekingalpha.com/pr/16783597-alliqua-biomedical-inc-announces-proposed-public-offering-common-stock\" target=\"_blank\">announcement </a>of a public offering of common stock. Price, volume and terms have yet to be announced. Net proceeds will fund working capital and general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253996\" data-linked=\"Alliqua Bio readies equity offering; shares slip 17% after hours\" data-tweet=\"$ALQA $ADYX - Alliqua Bio readies equity offering; shares slip 17% after hours https://seekingalpha.com/news/3253996-alliqua-bio-readies-equity-offering-shares-slip-17-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3253996-alliqua-bio-readies-equity-offering-shares-slip-17-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:39 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253993\" data-ts=\"1490732862\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASRT\" target=\"_blank\">ASRT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253993-depomed-inks-cooperative-deal-activist-investor-to-shake-up-board-and-name-new-ceo-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Depomed inks cooperative deal with activist investor to shake-up board and name new CEO; shares down 6% after hours on soft Q1 guidance</a></h4><ul><li>Depomed (DEPO) and activist investor Starboard Value LP have reached an <a href=\"https://seekingalpha.com/pr/16783542-depomed-announces-cooperation-agreement-starboard-value-lp-including-ceo-board-changes\" target=\"_blank\">agreement </a>on new leadership for the company. Former Bayer Healthcare CEO Arthur Higgins has been appointed President &amp; CEO.</li><li>Mr. Higgins, former Barr Pharmaceuticals CFO William McKee and Starboard partner Gavin Molinelli have joined the board. Directors Samuel Saks, M.D. and David Zenoff, D.B.A., have resigned. Currently director James Fogarty will be the new Chairman.</li><li>Separately, the company expects top-line revenues for Q1 of $95M - 100M. Management will update its 2017 guidance during its earnings call the week of May 8.</li><li>Shares are off&nbsp;<font color='red'>6%</font>&nbsp;after hours on increased volume in response to the soft revenue guidance. The midpoint represents a yoy decrease of 7%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253993\" data-linked=\"Depomed inks cooperative deal with activist investor to shake-up board and name new CEO; shares down 6% after hours on soft Q1 guidance\" data-tweet=\"$ASRT - Depomed inks cooperative deal with activist investor to shake-up board and name new CEO; shares down 6% after hours on soft Q1 guidance https://seekingalpha.com/news/3253993-depomed-inks-cooperative-deal-activist-investor-to-shake-up-board-and-name-new-ceo-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3253993-depomed-inks-cooperative-deal-activist-investor-to-shake-up-board-and-name-new-ceo-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253991\" data-ts=\"1490732736\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OLLI\" target=\"_blank\">OLLI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253991-post-earnings-gain-for-ollies-bargain-outlet-holdings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Post-earnings gain for Ollie&#39;s Bargain Outlet Holdings</a></h4><ul>     <li>Ollie's Bargain Outlet Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/OLLI' title='Ollie&#39;s Bargain Outlet Holdings'>OLLI</a>) is higher after topping consensus estimates with its <a href=\"https://seekingalpha.com/pr/16783571-ollie-s-bargain-outlet-holdings-inc-announces-fiscal-2016-fourth-quarter-full-year-financial\" target=\"_blank\">FQ4 report</a>.</li>     <li>Comparable sales were up 2.0% to match consensus and total sales increased 16% to $283M on a higher store count.</li>     <li>The company's gross profit rate was down 60 bps to 40.0%. Cost of sales were up 60 bps to 60.0% of sales. Net income came in at 8.6% of sales vs. 6.6% a year ago.</li>   <li>\"Very strong deal flow, consistent performance across all stores and tight expense control helped drive strong bottom line results,\" says CEO Mark Butler.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3253980-ollies-bargain-outlet-beats-0_04-beats-revenue\" target=\"_blank\">Ollie's Bargain Outlet beats by $0.04, beats on revenue</a> (March 28)</li>      <li>OLLI <font color='green'>+3.32%</font> premarket to $34.20.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253991\" data-linked=\"Post-earnings gain for Ollie&#39;s Bargain Outlet Holdings\" data-tweet=\"$OLLI - Post-earnings gain for Ollie&#39;s Bargain Outlet Holdings https://seekingalpha.com/news/3253991-post-earnings-gain-for-ollies-bargain-outlet-holdings?source=tweet\" data-url=\"https://seekingalpha.com/news/3253991-post-earnings-gain-for-ollies-bargain-outlet-holdings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253984\" data-ts=\"1490732368\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLAY\" target=\"_blank\">PLAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253984-comparable-sales-bit-short-for-dave-busters\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Comparable sales a bit short for Dave &amp; Buster&#39;s</a></h4><ul>     <li>Dave &amp; Buster's Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a>) trades lower after coming up short with sales at existing stores in <a href=\"https://seekingalpha.com/pr/16783558-dave-and-buster-s-achieves-fourth-quarter-net-income-growth-19-percent\" target=\"_blank\">Q4</a>.</li>     <li>The company reports comparable sales increased 3.1% during the quarter vs. +3.7% consensus and +6% a year ago.</li>     <li>Adjusted EBITDA increased 30 bps Y/Y to 27.6% of sales during the quarter.</li>     <li>The company expects FY17 revenue of $1.16B to $1.17B vs. $1.16B consensus off of comparable sales growth of 2% to 3%. 11 to 12 store openings are expected this year.</li> <li>\"Our consistent performance and industry-leading margins position us well for our next growth phase. At the same time, our free cash flow and strong balance sheet allow flexibility to return value to shareholders in additional ways, including share repurchases,\" says CFO Brian Jenkins.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3253973-dave-and-busters-beats-0_04-beats-revenue\" target=\"_blank\">Dave &amp; Buster's beats by $0.04, beats on revenue</a> (March 28)</li>     <li>PLAY&nbsp;<font color='red'>-5.61%</font>&nbsp;AH to $58.70.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253984\" data-linked=\"Comparable sales a bit short for Dave &amp; Buster&#39;s\" data-tweet=\"$PLAY - Comparable sales a bit short for Dave &amp; Buster&#39;s https://seekingalpha.com/news/3253984-comparable-sales-bit-short-for-dave-busters?source=tweet\" data-url=\"https://seekingalpha.com/news/3253984-comparable-sales-bit-short-for-dave-busters\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253980\" data-ts=\"1490732007\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OLLI\" target=\"_blank\">OLLI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253980-ollies-bargain-outlet-beats-0_04-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ollie&#39;s Bargain Outlet beats by $0.04, beats on revenue</a></h4><ul><li>Ollie's Bargain Outlet (NASDAQ:<a href='https://seekingalpha.com/symbol/OLLI' title='Ollie&#39;s Bargain Outlet Holdings'>OLLI</a>): Q4 EPS of $0.39 <font color='green'>beats by $0.04</font>.</li><li>Revenue of $283.4M (+16.4% Y/Y) <font color='green'>beats by $3.02M</font>.</li><li>Shares <font color='green'>+2.57%</font>.</li><li><a href='https://seekingalpha.com/pr/16783571-ollie-s-bargain-outlet-holdings-inc-announces-fiscal-2016-fourth-quarter-full-year-financial'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3253980\" data-linked=\"Ollie&#39;s Bargain Outlet beats by $0.04, beats on revenue\" data-tweet=\"$OLLI - Ollie&#39;s Bargain Outlet beats by $0.04, beats on revenue https://seekingalpha.com/news/3253980-ollies-bargain-outlet-beats-0_04-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3253980-ollies-bargain-outlet-beats-0_04-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253978\" data-ts=\"1490731870\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SONC\" target=\"_blank\">SONC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253978-sales-drop-sonic-worse-anticipated\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sales drop at Sonic worse than anticipated</a></h4><ul>     <li>Sonic (NASDAQ:<a href='https://seekingalpha.com/symbol/SONC' title='Sonic Corp.'>SONC</a>) reports same-store sales fell 7.4% in <a href=\"https://seekingalpha.com/pr/16783545-sonic-reports-second-fiscal-quarter-earnings-per-share-growth-14-percent-driven-refranchising\" target=\"_blank\">FQ2</a> as the chain lost market share. Analysts expected same-store sales to be down about 4.5%.</li>     <li>Drive-in margins at company-owned stores fell 210 bps during the quarter. Food and packaging costs at company drive-ins as a percentage of sales fell 10 bps to 27.4%. Payroll and employee benefits were up 230 bps to 39.4% of sales.</li>     <li>Sonic store count +34 Y/Y to 3,562.</li>     <li>\"Our second quarter results reflect a sluggish consumer environment, weather headwinds and share losses following exceptionally strong performance over the prior two years,\" notes Sonic CEO Cliff Hudson.</li>     <li>Guidance: The company forecasts FY17 same-store sales growth of -2% to 0%. Drive-in-level margins are seen falling in a range of 15.5% to 16.0% vs. 16% to 17% pior view. Sonic expects to open 65 to 75 new franchised drive-in locations during the year.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3253970-sonic-beats-0_01-misses-revenue\" target=\"_blank\">Sonic beats by $0.01, misses on revenue</a> (March 28)</li>     <li>SONC <font color='red'>-4.26% </font>AH to $22.90.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253978\" data-linked=\"Sales drop at Sonic worse than anticipated\" data-tweet=\"$SONC - Sales drop at Sonic worse than anticipated https://seekingalpha.com/news/3253978-sales-drop-sonic-worse-anticipated?source=tweet\" data-url=\"https://seekingalpha.com/news/3253978-sales-drop-sonic-worse-anticipated\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253972\" data-ts=\"1490731682\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RH\" target=\"_blank\">RH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253972-rh-beats-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RH beats by $0.03, beats on revenue</a></h4><ul><li>RH (NYSE:<a href='https://seekingalpha.com/symbol/RH' title='RH'>RH</a>): Q4 EPS of $0.68 <font color='green'>beats by $0.03</font>.</li><li>Revenue of $586.7M (-9.3% Y/Y) <font color='green'>beats by $1.7M</font>.</li><li>Shares <font color='green'>+8%</font>.</li><li><a href=\"https://seekingalpha.com/pr/16783553-rh-reports-fourth-quarter-fiscal-2016-financial-results\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3253972\" data-linked=\"RH beats by $0.03, beats on revenue\" data-tweet=\"$RH - RH beats by $0.03, beats on revenue https://seekingalpha.com/news/3253972-rh-beats-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3253972-rh-beats-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253962\" data-ts=\"1490731160\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRTO\" target=\"_blank\">CRTO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253962-shot-in-publisher-ad-tech-war-guardian-sues-rubicon-project\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">A shot in publisher/ad-tech war: Guardian sues Rubicon Project</a></h4><ul>   <li><i>The Guardian</i> newspaper is <a href=\"http://digiday.com/media/gloves-off-guardian-sues-rubicon-project-undisclosed-fees/\" target=\"_blank\">suing the Rubicon Project</a> (<a href=\"http://seekingalpha.com/symbol/RUBI\" target=\"_blank\">RUBI</a> <font color='red'>-1.7%</font>), charging that the ad-tech firm didn't disclose its buyer fees when pursuing <i>Guardian</i> inventory.</li>    <li>It's a spillover of tension between ad-tech and publishing as programmatic ads take over display advertising, crimping publishers' takes to make more revenue room for data vendors.</li>    <li>In the Guardian's case, the paper ran an investigation of its inventory to find it was receiving 30 pence for each pound's worth of programmatic ads. And 80% of its digital display inventory was sold that way over the past three months.</li>    <li>Rubicon Project responds: \"&ldquo;Without buyer fees we would need to charge sellers more, and we think our approach is fair ... We split our fees between sellers and buyers, reflecting the value we provide to both.&rdquo;</li>    <li>Also lower today: <a href='https://seekingalpha.com/symbol/CRTO' title='Criteo S.A.'>CRTO</a> <font color='red'>-2.5%</font>, <a href='https://seekingalpha.com/symbol/FUEL' title='Rocket Fuel'>FUEL</a> <font color='red'>-3.7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253962\" data-linked=\"A shot in publisher/ad-tech war: Guardian sues Rubicon Project\" data-tweet=\"$CRTO $CRTO $FUEL - A shot in publisher/ad-tech war: Guardian sues Rubicon Project https://seekingalpha.com/news/3253962-shot-in-publisher-ad-tech-war-guardian-sues-rubicon-project?source=tweet\" data-url=\"https://seekingalpha.com/news/3253962-shot-in-publisher-ad-tech-war-guardian-sues-rubicon-project\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253964\" data-ts=\"1490731031\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GG\" target=\"_blank\">GG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253964-goldcorpminus-7-investors-cool-to-costs-of-chilean-joint-venture-barrick\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldcorp -7% as investors cool to costs of Chilean joint venture with Barrick</a></h4><ul>     <li>Goldcorp (<a href='https://seekingalpha.com/symbol/GG' title='Goldcorp Inc.'>GG</a> <font color='red'>-6.9%</font>) plunges nearly 7% after <a href=\"http://business.financialpost.com/news/mining/barrick-gold-corp-goldcorp-inc-team-up-to-explore-mines-in-chile-as-industry-gears-up-for-growth-again\" target=\"_blank\">committing nearly $1B</a>, including ~$445M in upfront costs, to a <a href=\"https://seekingalpha.com/news/3253821-goldcorp-team-barrick-consolidate-cerro-casale-caspiche-projects\" target=\"_blank\">joint venture</a> with Barrick Gold (ABX <font color='red'>-2.6%</font>) that will see the companies own and operate at least three properties in Chile&rsquo;s Maricunga region.</li>     <li>The announcements are a &ldquo;<a href=\"https://www.bloomberg.com/news/articles/2017-03-28/barrick-goldcorp-team-up-in-chile-as-miners-look-to-share-risk\" target=\"_blank\">slight strategic negative</a>&rdquo; for GG, according to Goldman Sachs' Andrew Quail, saying the deals highlight the company&rsquo;s \"lack of large-scale organic growth projects when compared to its peers&rdquo; such as ABX and Newmont Mining; the deal is &ldquo;strategically neutral&rdquo; for ABX, Quail says, but could become positive as it represents a move toward risk-sharing among large miners.</li>     <li>For GG, investors are unsure whether what was likely to be a big capital project would have a <a href=\"http://www.nasdaq.com/article/more-gold-mining-partnerships-seen-as-industry-eyes-growth-20170328-01028\" target=\"_blank\">high enough rate of return</a>, Gabelli Gold Fund research analyst Chris Mancini says, adding that development partnerships could make sense on other big gold projects, such as Seabridge Gold's (<a href='https://seekingalpha.com/symbol/SA' title='Seabridge Gold Inc'>SA</a> <font color='red'>-0.4%</font>) KSM project in Canada and Northern Dynasty's (<a href='https://seekingalpha.com/symbol/NAK' title='Northern Dynasty Minerals Ltd'>NAK</a> <font color='red'>-3.5%</font>) Pebble deposit in Alaska.</li>     <li>The impact of the deal on GG is &ldquo;<a href=\"http://blogs.barrons.com/stockstowatchtoday/2017/03/28/why-goldcorp-is-tumbling/\" target=\"_blank\">neutral to slight positive</a>,\"&nbsp;GMP&nbsp;Securities' Steven Butler says, as the purchase prices look reasonable but much depends on future direction of commodity prices, capex estimates, timing of development and competition with other projects.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253964\" data-linked=\"Goldcorp -7% as investors cool to costs of Chilean joint venture with Barrick\" data-tweet=\"$GG $GG $GOLD - Goldcorp -7% as investors cool to costs of Chilean joint venture with Barrick https://seekingalpha.com/news/3253964-goldcorpminus-7-investors-cool-to-costs-of-chilean-joint-venture-barrick?source=tweet\" data-url=\"https://seekingalpha.com/news/3253964-goldcorpminus-7-investors-cool-to-costs-of-chilean-joint-venture-barrick\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253960\" data-ts=\"1490730749\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RCAR\" target=\"_blank\">RCAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253960-renovacare-reports-fy16-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RenovaCare reports FY16 results</a></h4><ul><li>RenovaCare (<a href='https://seekingalpha.com/symbol/RCAR' title='RenovaCare, Inc.'>OTCPK:RCAR</a>): FY16 EPS of -$0.03 vs. -$0.02 in FY15</li><li>Cash and equivalents of $0.42M</li><li>Shares <font color='green'>+3%</font>.</li><li><a href=\"https://seekingalpha.com/filing/3477166?app=1&amp;uprof=44\" target=\"_blank\">Press Release</a></li><li>See important&nbsp;<a href=\"http://seekingalpha.com/page/corporate-visibility-program\" target=\"_blank\">disclosures</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253960\" data-linked=\"RenovaCare reports FY16 results\" data-tweet=\"$RCAR - RenovaCare reports FY16 results https://seekingalpha.com/news/3253960-renovacare-reports-fy16-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3253960-renovacare-reports-fy16-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253957\" data-ts=\"1490730044\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DFFN\" target=\"_blank\">DFFN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253957-diffusion-pharma-up-60-on-new-patent-covering-lead-product-candidate-tsc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Diffusion Pharma up 60% on new patent covering lead product candidate TSC</a></h4><ul><li>Thinly traded nano cap Diffusion Pharmaceuticals (<a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a> <font color='green'>+60.2%</font>) is up on a healthy 16x surge in volume in response to the <a href=\"https://www.benzinga.com/news/17/03/9224856/diffusion-pharma-shares-spike-26-as-hearing-co-has-won-new-us-patent-related-to-t\" target=\"_blank\">news </a>that it has secured a new patent covering lead product candidate <a href=\"http://www.diffusionpharma.com/product-pipeline/overview-trans-sodium-crocetinate-tsc/\" target=\"_blank\">Trans Sodium Crocetinate</a> &#40;TSC&#41;.</li><li>Orphan Drug-tagged TSC is a small molecule that modifies the tumor microenvironment which improves the effectiveness of radiation therapy and chemotherapy.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253957\" data-linked=\"Diffusion Pharma up 60% on new patent covering lead product candidate TSC\" data-tweet=\"$DFFN - Diffusion Pharma up 60% on new patent covering lead product candidate TSC https://seekingalpha.com/news/3253957-diffusion-pharma-up-60-on-new-patent-covering-lead-product-candidate-tsc?source=tweet\" data-url=\"https://seekingalpha.com/news/3253957-diffusion-pharma-up-60-on-new-patent-covering-lead-product-candidate-tsc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253959\" data-ts=\"1490729289\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMC\" target=\"_blank\">CMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253959-commercial-metals-upgraded-to-outperform-credit-suisse\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Commercial Metals upgraded to Outperform at Credit Suisse</a></h4><ul>     <li>Commercial Metals (NYSE:<a href='https://seekingalpha.com/symbol/CMC' title='Commercial Metals Company'>CMC</a>) surges higher after Credit Suisse <a href=\"https://www.thestreet.com/story/14062630/1/commercial-metals-stock-climbing-on-credit-suisse-upgrade.html\" target=\"_blank\">upgrades</a> shares to Outperform from Neutral with a $24 price target, raised from $19, saying CMC should see \"significant\" EBITDA growth during 2017-19, driven by solid volume growth and metal spread expansion.</li><li>The firm sees a rebound in global rebar markets driven by capacity  rationalization in China, accelerating global demand and lower export  volumes from China.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253959\" data-linked=\"Commercial Metals upgraded to Outperform at Credit Suisse\" data-tweet=\"$CMC - Commercial Metals upgraded to Outperform at Credit Suisse https://seekingalpha.com/news/3253959-commercial-metals-upgraded-to-outperform-credit-suisse?source=tweet\" data-url=\"https://seekingalpha.com/news/3253959-commercial-metals-upgraded-to-outperform-credit-suisse\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:28 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253952\" data-ts=\"1490728290\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHK\" target=\"_blank\">CHK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253952-chesapeake-energyplus-3-after-bullish-view-from-wunderlich-analyst\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chesapeake Energy +3% after bullish view from Wunderlich analyst</a></h4><ul>     <li>Chesapeake Energy (<a href='https://seekingalpha.com/symbol/CHK' title='Chesapeake Energy Corporation'>CHK</a> <font color='green'>+3.2%</font>) powers higher in active trading as Wunderlich analyst Jason Wrangler reiterates a <a href=\"http://blogs.barrons.com/stockstowatchtoday/2017/03/28/chesapeake-energy-a-good-start/\" target=\"_blank\">Buy rating</a> and $10 price target on the shares, citing \"compelling valuation alongside natural gas exposure, oil growth and an improving balance sheet.\"</li>     <li>CHK&rsquo;s early results from its Powder River Basin and Mid-Continent plays are \"positive developments as the company ramps activity in the areas with a focus on driving oil growth going forward,\" Wrangler writes.</li>     <li>The analyst notes that CHK recently posted a 1,650 boe/day (70% oil) Niobrara well test on its Powder River Basin assets, \"a good start\" as the company ramps up operations in the region.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253952\" data-linked=\"Chesapeake Energy +3% after bullish view from Wunderlich analyst\" data-tweet=\"$CHK - Chesapeake Energy +3% after bullish view from Wunderlich analyst https://seekingalpha.com/news/3253952-chesapeake-energyplus-3-after-bullish-view-from-wunderlich-analyst?source=tweet\" data-url=\"https://seekingalpha.com/news/3253952-chesapeake-energyplus-3-after-bullish-view-from-wunderlich-analyst\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>69&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253951\" data-ts=\"1490727603\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253951-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/IZEA' title='IZEA Worldwide, Inc.'>IZEA</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/GRVY' title='GRAVITY Co., Ltd. - American depositary shares, each representing one'>GRVY</a> <font color='green'>+22%</font>. DRAM <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/PRKR' title='ParkerVision, Inc.'>OTC:PRKR</a> <font color='green'>+10%</font>. COOL <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SCON' title='Superconductor Technologies Inc.'>SCON</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/NIHD' title='NII Holdings, Inc.'>NIHD</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/EMAN' title='eMagin Corporation'>EMAN</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/DGLY' title='Digital Ally, Inc.'>DGLY</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/INAP' title='Internap Network Services Corporation'>INAP</a> <font color='red'>-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253951\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$IZEA $GRVY $USAU - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3253951-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3253951-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253944\" data-ts=\"1490725193\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TS\" target=\"_blank\">TS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253944-tenarisplus-5-on-bullish-outlook-for-global-oil-tubes-market\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tenaris +5% on bullish outlook for global oil tubes market</a></h4><ul>     <li>Tenaris (<a href='https://seekingalpha.com/symbol/TS' title='Tenaris S.A.'>TS</a> <font color='green'>+5.6%</font>) jumps after <a href=\"http://www.reuters.com/article/tenaris-ocgt-idUSL5N1H55M9\" target=\"_blank\">lifting its 2017 demand estimate</a> for global tubular goods used in oil and gas production to 12.1M metric tons from a previous forecast of 10.4M tons and 2016 demand of 8.8M tons.</li>     <li>TS sees demand this year in the U.S. and Canada reaching 5.2M metric tons, up from 2.2M last year, demand from China and Russia rising to 3.7M tons from 3.5M a year ago, and demand in other areas remaining stable.</li>     <li>The new guidance could result in a double-digit upgrade to analyst earnings estimates for TS, a trader tells Reuters.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253944\" data-linked=\"Tenaris +5% on bullish outlook for global oil tubes market\" data-tweet=\"$TS - Tenaris +5% on bullish outlook for global oil tubes market https://seekingalpha.com/news/3253944-tenarisplus-5-on-bullish-outlook-for-global-oil-tubes-market?source=tweet\" data-url=\"https://seekingalpha.com/news/3253944-tenarisplus-5-on-bullish-outlook-for-global-oil-tubes-market\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253943\" data-ts=\"1490724404\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253943-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/XRA' title='Exeter Resource Corporation'>XRA</a> <font color='green'>+53%</font>. <a href='https://seekingalpha.com/symbol/MBII' title='Marrone Bio Innovations, Inc.'>MBII</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/BCEI' title='Bonanza Creek Energy'>BCEI</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/REI' title='Ring Energy, Inc.'>REI</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/SDRL' title='Seadrill Limited &#40;New&#41;'>SDRL</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/GSV' title='Gold Standard Ventures'>GSV</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/GEVO' title='Gevo, Inc.'>GEVO</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/GG' title='Goldcorp Inc.'>GG</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/RIC' title='Richmont Mines, Inc'>RIC</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253943\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$XRA $MBII $BCEI - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3253943-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3253943-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253933\" data-ts=\"1490720185\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NSM\" target=\"_blank\">NSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253933-nationstar-mortgage-up-nearly-7-after-positive-coverage\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nationstar Mortgage up nearly 7% after positive coverage</a></h4><ul><li>Wedbush buys the dip, initiating coverage with an Outperform rating with the $19 price target suggesting more than&nbsp;<font color='green'>25% upside</font>&nbsp;from yesterday's close.</li><li>This year should be a \"transitional\" one for Nationstar (<a href='https://seekingalpha.com/symbol/NSM' title='Nationstar Mortgage Holdings'>NSM</a> <font color='green'>+6.7%</font>), says analyst Henry Coffey, with the benefits of its growth strategy becoming more apparent in 2018.</li><li>Source: Bloomberg</li><li>The specialty servicer sector as a whole is lit up bright green, including Ocwen Financial (<a href='https://seekingalpha.com/symbol/OCN' title='Ocwen Financial Corporation'>OCN</a> <font color='green'>+7.4%</font>), which took another big step towards cutting cots, and once again being a buyer of MSRs, courtesy of <a href=\"https://seekingalpha.com/news/3253698-ocwen-settles-nydfs-shares-plus-3_7-percent-hours\" target=\"_blank\">last night's announced settlement</a> with the NYDFS.</li><li>One beneficiary should be Altisource Portfolio Solutions (<a href='https://seekingalpha.com/symbol/ASPS' title='Altisource Portfolio Solutions SA'>ASPS</a> <font color='green'>+7.3%</font>) which should see more business if Ocwen moves back into growth mode.</li><li>Walter Investment (WAC <font color='green'>+19%</font>), New Residential (<a href='https://seekingalpha.com/symbol/NRZ' title='New Residential Investment Corp.'>NRZ</a> <font color='green'>+1.3%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3253933\" data-linked=\"Nationstar Mortgage up nearly 7% after positive coverage\" data-tweet=\"$NSM $NSM $OCN - Nationstar Mortgage up nearly 7% after positive coverage https://seekingalpha.com/news/3253933-nationstar-mortgage-up-nearly-7-after-positive-coverage?source=tweet\" data-url=\"https://seekingalpha.com/news/3253933-nationstar-mortgage-up-nearly-7-after-positive-coverage\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253932\" data-ts=\"1490719946\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TDW\" target=\"_blank\">TDW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253932-tidewaterplus-11-stops-seeking-waiver-extensions\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tidewater +11% as it stops seeking more waiver extensions</a></h4><ul>     <li>Tidewater (<a href='https://seekingalpha.com/symbol/TDW' title='Tidewater, Inc.'>TDW</a> <font color='green'>+11%</font>) posts strong gains after saying it will <a href=\"https://seekingalpha.com/pr/16782205-tidewater-announces-expiration-limited-waivers-lenders-noteholders\" target=\"_blank\">not seek renewal of limited waivers</a> from its lenders and noteholders following yesterday's expiration of the latest one.</li>     <li>TDW has been in talks since last year with its principal lenders and noteholders to amend its various debt arrangements to obtain relief from certain covenants.</li><li>TDW&nbsp;CEO&nbsp;Jeffrey Platt says work remains to resolve \"a small number of issues\" and to obtain board  approval as well as final approval from the various  financial institutions.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253932\" data-linked=\"Tidewater +11% as it stops seeking more waiver extensions\" data-tweet=\"$TDW - Tidewater +11% as it stops seeking more waiver extensions https://seekingalpha.com/news/3253932-tidewaterplus-11-stops-seeking-waiver-extensions?source=tweet\" data-url=\"https://seekingalpha.com/news/3253932-tidewaterplus-11-stops-seeking-waiver-extensions\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253931\" data-ts=\"1490719800\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253931-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a> <font color='green'>+203%</font>. <a href='https://seekingalpha.com/symbol/XRA' title='Exeter Resource Corporation'>XRA</a> <font color='green'>+54%</font>. <a href='https://seekingalpha.com/symbol/AKER' title='Akers Biosciences Inc.'>AKER</a> <font color='green'>+52%</font>. <a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a> <font color='green'>+40%</font>. <a href='https://seekingalpha.com/symbol/PSIX' title='Power Solutions International, Inc.'>OTCPK:PSIX</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/GRVY' title='GRAVITY Co., Ltd. - American depositary shares, each representing one'>GRVY</a> <font color='green'>+25%</font>. SSH <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/IMMY-OLD' title='Imprimis Pharmaceuticals, Inc.'>IMMY-OLD</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/OSIR' title='Osiris Therapeutics, Inc.'>OSIR</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/KBSF' title='KBS Fashion Group Limited'>KBSF</a> <font color='green'>+18%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CYRX' title='CryoPort, Inc.'>CYRX</a> <font color='red'>-45%</font>. <a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a> <font color='red'>-25%</font>. <a href='https://seekingalpha.com/symbol/APOP' title='Cellect Biotechnology Ltd.'>APOP</a> <font color='red'>-24%</font>. <a href='https://seekingalpha.com/symbol/CGIX' title='Cancer Genetics, Inc.'>CGIX</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/VSR' title='Versar, Inc'>VSR</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/XELB' title='Xcel Brands, Inc.'>XELB</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/EMAN' title='eMagin Corporation'>EMAN</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/SCON' title='Superconductor Technologies Inc.'>SCON</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/INAP' title='Internap Network Services Corporation'>INAP</a> <font color='red'>-11%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253931\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$CBIO $XRA $AKER - Midday Gainers / Losers https://seekingalpha.com/news/3253931-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3253931-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253930\" data-ts=\"1490719543\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IBA\" target=\"_blank\">IBA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253930-bachoco-on-watch-after-large-recall\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bachoco on watch after large recall</a></h4><ul> <li>Shares of Industrias Bachoco (<a href='https://seekingalpha.com/symbol/IBA' title='Industrias Bachoco, S.A.B. de C.V.'>IBA</a> <font color='red'>-0.6%</font>) are on watch after the company recalls almost 1M pounds of OK Foods breaded chicken products being sold in the U.S. under different brand names.</li> <li>Bachoco acquired Arkansas-based OK Foods in 2011.</li> <li><a href=\"https://www.fsis.usda.gov/wps/portal/fsis/topics/recalls-and-public-health-alerts/recall-case-archive/archive/2017/recall-030-2017-release\" target=\"_blank\">Department of Agriculture press release</a></li>  </ul><div class=\"tiny-share-widget\" data-id=\"3253930\" data-linked=\"Bachoco on watch after large recall\" data-tweet=\"$IBA - Bachoco on watch after large recall https://seekingalpha.com/news/3253930-bachoco-on-watch-after-large-recall?source=tweet\" data-url=\"https://seekingalpha.com/news/3253930-bachoco-on-watch-after-large-recall\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253929\" data-ts=\"1490719399\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTNB\" target=\"_blank\">MTNB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253929-matinas-bio-adds-to-trial-related-gains\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Matinas Bio adds to trial-related gains</a></h4><ul>     <li>Matinas BioPharma (<a href='https://seekingalpha.com/symbol/MTNB' title='Matinas Biopharma Holdings, Inc.'>MTNB</a> <font color='green'>+2%</font>) yesterday <a href=\"https://seekingalpha.com/news/3253588-matinas-biopharma-reports-positive-topline-data-phase-1-study-mat2501-shares-plus-4-percent\" target=\"_blank\">reported positive topline data</a> from its Phase 1 study of MAT2501.</li>     <li>Trading at $1.65 late on Friday afternoon, shares are currently changing hands at $2.65.</li>     <li>See important <a href=\"https://seekingalpha.com/page/corporate-visibility-program\" target=\"_blank\">disclosures</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253929\" data-linked=\"Matinas Bio adds to trial-related gains\" data-tweet=\"$MTNB - Matinas Bio adds to trial-related gains https://seekingalpha.com/news/3253929-matinas-bio-adds-to-trial-related-gains?source=tweet\" data-url=\"https://seekingalpha.com/news/3253929-matinas-bio-adds-to-trial-related-gains\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:43 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253923\" data-ts=\"1490719324\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AUPH\" target=\"_blank\">AUPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253923-aurinia-continues-intermediate-correction-from-voclosporin-stoked-run-up-shares-ease-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aurinia continues intermediate correction from voclosporin-stoked run-up; shares ease 9%</a></h4><ul><li>Aurinia Pharmaceuticals (<a href='https://seekingalpha.com/symbol/AUPH' title='Aurinia Pharmaceuticals Inc.'>AUPH</a> <font color='red'>-8.5%</font>) continues its correction from the three-fold up move that started at the beginning of the month after it reported positive results from a Phase 2b study of voclosporin in patients with lupus nephritis &#40;LN&#41;. Shares are down over&nbsp;<font color='red'>33%</font>&nbsp;from the peak of $10.54 on March 13.</li><li>This morning, SA <a href=\"https://seekingalpha.com/article/4058459-aurinia-pharmaceuticals-highlighting-important-clinical-regulatory-change\" target=\"_blank\">published an article</a> on the company from first-time Contributor Element Capital Research that raises questions about the efficacy of calcineurin inhibitors in LN and potential risks to the success of the Phase 3 study if renal biopsies are required since it would make it more difficult to prove voclosporin works.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253923\" data-linked=\"Aurinia continues intermediate correction from voclosporin-stoked run-up; shares ease 9%\" data-tweet=\"$AUPH - Aurinia continues intermediate correction from voclosporin-stoked run-up; shares ease 9% https://seekingalpha.com/news/3253923-aurinia-continues-intermediate-correction-from-voclosporin-stoked-run-up-shares-ease-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3253923-aurinia-continues-intermediate-correction-from-voclosporin-stoked-run-up-shares-ease-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253926\" data-ts=\"1490719133\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMASY\" target=\"_blank\">IMASY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253926-rbc-raises-inmarsat-to-outperform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RBC raises Inmarsat to Outperform</a></h4><ul>   <li>Inmarsat (<a href='https://seekingalpha.com/symbol/IMASY' title='Inmarsat Plc. ADR'>OTCPK:IMASY</a>) has gotten boosted to Outperform by RBC Capital Markets, from a previous Outperform.</li>    <li>Analyst Wilton Fry raised his price target on the satcom provider to 1,000 pence from 760 pence, implying 23% upside from current price.</li>    <li>Shares closed <font color='green'>up 2.6%</font> today in London.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253926\" data-linked=\"RBC raises Inmarsat to Outperform\" data-tweet=\"$IMASY $IMASF - RBC raises Inmarsat to Outperform https://seekingalpha.com/news/3253926-rbc-raises-inmarsat-to-outperform?source=tweet\" data-url=\"https://seekingalpha.com/news/3253926-rbc-raises-inmarsat-to-outperform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253925\" data-ts=\"1490718944\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PSIX\" target=\"_blank\">PSIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253925-power-solutions-upgraded-to-hold-lake-street-on-chinese-investment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Power Solutions upgraded to Hold at Lake Street on Chinese investment</a></h4><ul><li>Power Solutions International (<a href='https://seekingalpha.com/symbol/PSIX' title='Power Solutions International, Inc.'>OTCPK:PSIX</a> <font color='green'>+25.5%</font>) is <a href=\"http://www.mmahotstuff.com/2017/03/28/lake-street-ups-power-solutions-international-psix-to-hold-profile-of-1-analysts-covering-santander-mexico-fincl-gp-sab-decv-adr-bsmx.html\" target=\"_blank\">upgraded</a> to Hold from Sell with a $9 price target at Lake Street, which says the <a href=\"https://seekingalpha.com/news/3253693-power-solutions-plus-54-percent-chinese-firm-commits-60m-investment\" target=\"_blank\">strategic investment</a> by Weichai has removed the risk of bankruptcy.</li><li>Lake Street says the deal also adds the largest engine manufacturer in China as a strategic  partner that accelerates PSIX's efforts in China and results in sourcing  and manufacturing synergies.</li><li>The firm thinks Weichai's $8/share  valuation price of the investment - a 25% premium to yesterday's closing price - is an attractive valuation of 9x EV/EBITDA based on its 2017 EBITDA estimate.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253925\" data-linked=\"Power Solutions upgraded to Hold at Lake Street on Chinese investment\" data-tweet=\"$PSIX - Power Solutions upgraded to Hold at Lake Street on Chinese investment https://seekingalpha.com/news/3253925-power-solutions-upgraded-to-hold-lake-street-on-chinese-investment?source=tweet\" data-url=\"https://seekingalpha.com/news/3253925-power-solutions-upgraded-to-hold-lake-street-on-chinese-investment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253920\" data-ts=\"1490716886\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253920-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/KBSF' title='KBS Fashion Group Limited'>KBSF</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/RELV' title='Reliv&#39; International, Inc.'>RELV</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/FFHL' title='Fuwei Films &#40;Holdings&#41; Co., Ltd.'>FFHL</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/VNCE' title='Vince Holding Corp.'>VNCE</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CYRX' title='CryoPort, Inc.'>CYRX</a> <font color='red'>-45%</font>. <a href='https://seekingalpha.com/symbol/FORD' title='Forward Industries, Inc.'>FORD</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SNAK' title='Inventure Foods, Inc.'>SNAK</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253920\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$KBSF $RELV $FFHL - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3253920-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3253920-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253915\" data-ts=\"1490715987\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHLDQ\" target=\"_blank\">SHLDQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253915-sears-holdingsplus-14-to-break-out-of-single-digits\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sears Holdings +14% to break out of single digits</a></h4><ul> <li>Sears Holdings (SHLD) is <font color='green'>up 13.5%</font>&nbsp;on elevated volume to swing back over $10 after yesterday's news of insider buying by Eddie Lampert and Fairholme Capital Management instills a bit of confidence.</li> <li>Execs with Sears continue to defend its SEC filing shocker last week as \"in line\" with regulatory standards.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3253574-sears-holdings-breaks-higher\" target=\"_blank\">Sears Holdings breaks higher</a> (March 27)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3253587-mall-store-closing-blitz-continues\" target=\"_blank\">Mall store closing blitz continues</a> (March 27)</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3253915\" data-linked=\"Sears Holdings +14% to break out of single digits\" data-tweet=\"$SHLDQ - Sears Holdings +14% to break out of single digits https://seekingalpha.com/news/3253915-sears-holdingsplus-14-to-break-out-of-single-digits?source=tweet\" data-url=\"https://seekingalpha.com/news/3253915-sears-holdingsplus-14-to-break-out-of-single-digits\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>54&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253914\" data-ts=\"1490715830\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REGN\" target=\"_blank\">REGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253914-fda-oks-regeneron-and-sanofis-dermatitis-med-dupixent\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Regeneron and Sanofi&#39;s dermatitis med Dupixent</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16783267-sanofi-regeneron-announce-fda-approval-dupixent-dupilumab-first-targeted-biologic-therapy\" target=\"_blank\">approves </a>Regeneron Pharmaceuticals (<a href='https://seekingalpha.com/symbol/REGN' title='Regeneron Pharmaceuticals, Inc.'>REGN</a> <font color='red'>-1.7%</font>) and Sanofi's (<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a> <font color='green'>+1.1%</font>) Dupixent (dupilumab) for the treatment of adults with moderate-to-severe atopic dermatitis &#40;AD&#41;.</li><li>Dupixent is a human monoclonal antibody that is designed to specifically inhibit overactive signaling of two key proteins, IL-4 and IL-13, which are believed to be major drivers of the persistent underlying inflammation in AD. Dupixent comes in a pre-filled syringe and can be self-administered as a subcutaneous injection every other week after an initial loading dose.</li><li>The wholesale acquisition cost &#40;WAC&#41; in the U.S. will be $37K/year.</li><li>The FDA accepted the BLA in late September under Priority Review.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253914\" data-linked=\"FDA OKs Regeneron and Sanofi&#39;s dermatitis med Dupixent\" data-tweet=\"$REGN $REGN $SNY - FDA OKs Regeneron and Sanofi&#39;s dermatitis med Dupixent https://seekingalpha.com/news/3253914-fda-oks-regeneron-and-sanofis-dermatitis-med-dupixent?source=tweet\" data-url=\"https://seekingalpha.com/news/3253914-fda-oks-regeneron-and-sanofis-dermatitis-med-dupixent\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253913\" data-ts=\"1490715686\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GEGYF\" target=\"_blank\">GEGYF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253913-genel-energy-again-cuts-reserves-estimate-for-key-field\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Genel Energy again cuts reserves estimate for key field</a></h4><ul>     <li>Genel Energy's (<a href='https://seekingalpha.com/symbol/GEGYF' title='Genel Energy PLC'>OTCPK:GEGYF</a> <font color='red'>-14.4%</font>) market value plunges to an all-time low after saying again that its flagship Taq Taq oilfield in Iraqi Kurdistan <a href=\"http://www.reuters.com/article/us-genel-energy-reserves-idUSKBN16Z0NQ\" target=\"_blank\">contains less crude than expected</a>.</li>     <li>Genel cuts its reserves estimate for its largest operational field, by nearly two-thirds to 59M barrels of oil, down from 172M barrels in 2015 and 683M in 2011, adding that it will book a $181M impairment in 2016; the company also is suspending its 2017 gross average production forecast for the field.</li>     <li>Production at Taq Taq continues to decline, with the field now producing ~19K bbl/day of oil, down from 36K at the end of 2016 and initial expectations of as much as 80K bbl/day.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253913\" data-linked=\"Genel Energy again cuts reserves estimate for key field\" data-tweet=\"$GEGYF - Genel Energy again cuts reserves estimate for key field https://seekingalpha.com/news/3253913-genel-energy-again-cuts-reserves-estimate-for-key-field?source=tweet\" data-url=\"https://seekingalpha.com/news/3253913-genel-energy-again-cuts-reserves-estimate-for-key-field\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253909\" data-ts=\"1490714719\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BSBR\" target=\"_blank\">BSBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253909-banco-santander-brasil-slumps-after-share-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Banco Santander Brasil slumps after share sale</a></h4><ul><li>Qatar Holdings is selling 80M share certificates, which could be increased by another 12M ADSs.</li><li><a href='https://seekingalpha.com/symbol/BSBR' title='Banco Santander &#40;Brasil&#41; S.A.'>BSBR</a>&nbsp;<font color='red'>-6.55%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3253909\" data-linked=\"Banco Santander Brasil slumps after share sale\" data-tweet=\"$BSBR - Banco Santander Brasil slumps after share sale https://seekingalpha.com/news/3253909-banco-santander-brasil-slumps-after-share-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3253909-banco-santander-brasil-slumps-after-share-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253903\" data-ts=\"1490713333\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDIUY\" target=\"_blank\">MDIUY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253903-telecom-italia-auditors-vivendis-influence-company-strong\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Telecom Italia auditors: Vivendi&#39;s influence at company strong</a></h4><ul>   <li>Vivendi (<a href=\"http://seekingalpha.com/symbol/VIVHY\" target=\"_blank\">VIVHY</a> <font color='green'>+0.4%</font>), top shareholder at Telecom Italia (<a href=\"http://seekingalpha.com/symbol/TI\" target=\"_blank\">TI</a> <font color='green'>+1.6%</font>), is in a <a href=\"https://twitter.com/bentolmachoff/status/846476110846017536\" target=\"_blank\">position to influence board members</a> at the telecom even without de facto control of the company, TI Chairman Giuseppe Recchi told Italy's Senate.</li>    <li>That's according to what auditors told TI, Recchi said, promising other details on what the auditors had to say to the company.</li>    <li>Italy's government has taken a strong interest in growing influence by the French media giant. Aside from antitrust rules limiting shares in both telecom and media, it considers some Italian companies of national interest, and Vivendi's significant stake in Mediaset (<a href='https://seekingalpha.com/symbol/MDIUY' title='Mediaset S.p.A. ADR'>OTCPK:MDIUY</a>) has led to speculation about whether it plans to combine the companies.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253903\" data-linked=\"Telecom Italia auditors: Vivendi&#39;s influence at company strong\" data-tweet=\"$MDIUY $MDIUY $VIVHY - Telecom Italia auditors: Vivendi&#39;s influence at company strong https://seekingalpha.com/news/3253903-telecom-italia-auditors-vivendis-influence-company-strong?source=tweet\" data-url=\"https://seekingalpha.com/news/3253903-telecom-italia-auditors-vivendis-influence-company-strong\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253883\" data-ts=\"1490713306\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253883-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a> <font color='green'>+229%</font>. <a href='https://seekingalpha.com/symbol/AKER' title='Akers Biosciences Inc.'>AKER</a> <font color='green'>+50%</font>. <a href='https://seekingalpha.com/symbol/OMER' title='Omeros Corporation'>OMER</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/OSIR' title='Osiris Therapeutics, Inc.'>OSIR</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/SELB' title='Selecta Biosciences'>SELB</a> <font color='green'>+15%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a> <font color='red'>-24%</font>. <a href='https://seekingalpha.com/symbol/APOP' title='Cellect Biotechnology Ltd.'>APOP</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/CGIX' title='Cancer Genetics, Inc.'>CGIX</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/AUPH' title='Aurinia Pharmaceuticals Inc.'>AUPH</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/RGLS' title='Regulus Therapeutics'>RGLS</a> <font color='red'>-10%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253883\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$CBIO $AKER $OMER - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3253883-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3253883-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253897\" data-ts=\"1490712705\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HMCBF\" target=\"_blank\">HMCBF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253897-home-capital-group-fires-ceo-shares-down-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Home Capital Group fires CEO; shares down more than 7%</a></h4><ul><li>Martin Reid <a href=\"https://www.bnn.ca/home-capital-group-fires-ceo-martin-reid-1.707687\" target=\"_blank\">has been fired as</a> CEO of the Canadian mortgage lender less than a year after taking on the job. His termination is effective immediately.</li><li>The move comes amid a probe into fraudulent mortgage documents allegedly prepared by some of the company's mortgage brokers.</li><li>\"Home Capital (<a href='https://seekingalpha.com/symbol/HMCBF' title='Home Capital Group Inc.'>OTCPK:HMCBF</a>) requires leadership that can bring to bear a renewed operational discipline, emphasis on risk management and controls, and focus on improving performance,&rdquo; says Chairman Kevin Smith.</li><li>The stock's&nbsp;<font color='red'>down 7.1%&nbsp;</font>in Toronto action.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253897\" data-linked=\"Home Capital Group fires CEO; shares down more than 7%\" data-tweet=\"$HMCBF - Home Capital Group fires CEO; shares down more than 7% https://seekingalpha.com/news/3253897-home-capital-group-fires-ceo-shares-down-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3253897-home-capital-group-fires-ceo-shares-down-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253892\" data-ts=\"1490711285\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBLK\" target=\"_blank\">SBLK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253892-rally-time-for-shipping-stocks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rally time for shipping stocks</a></h4><ul> <li>There's a rally in shipping stocks after Morgan Stanley entered the fray earlier today with a series of upgrades of dry bulk names.</li> <li>Gainers across the broad shipping sector include Star Bulk Carriers (<a href='https://seekingalpha.com/symbol/SBLK' title='Star Bulk Carriers Corp.'>SBLK</a> <font color='green'>+15.1%</font>), Safe Bulkers (<a href='https://seekingalpha.com/symbol/SB' title='Safe Bulkers Inc.'>SB</a> <font color='green'>+14.8%</font>), Genco Shipping &amp; Trading (<a href='https://seekingalpha.com/symbol/GNK' title='Genco Shipping & Trading Ltd.'>GNK</a> <font color='green'>+11.7%</font>), DryShips (<a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='green'>+8.2%</font>), Golden Ocean Group (<a href='https://seekingalpha.com/symbol/GOGL' title='Golden Ocean Group Limited'>GOGL</a> <font color='green'>+6.9%</font>), Scorpio Tankers (<a href='https://seekingalpha.com/symbol/STNG' title='Scorpio Tankers Inc.'>STNG</a> <font color='green'>+5.5%</font>), DHT Holdings (<a href='https://seekingalpha.com/symbol/DHT' title='DHT Holdings, Inc.'>DHT</a> <font color='green'>+5%</font>), Global Ship Lease (<a href='https://seekingalpha.com/symbol/GSL' title='Global Ship Lease, Inc'>GSL</a> <font color='green'>+5.9%</font>), Seaspan (<a href='https://seekingalpha.com/symbol/SSW' title='Seaspan Corporation'>SSW</a> <font color='green'>+4.2%</font>), Navios Maritime Partners (<a href='https://seekingalpha.com/symbol/NMM' title='Navios Maritime Partners L.P.'>NMM</a> <font color='green'>+6.2%</font>), Navios Maritime Acquisition (<a href='https://seekingalpha.com/symbol/NNA' title='Navios Maritime Acquisition Corporation'>NNA</a> <font color='green'>+3.5%</font>) and Eagle Bulk Shipping (<a href='https://seekingalpha.com/symbol/EGLE' title='Eagle Bulk Shipping Inc.'>EGLE</a> <font color='green'>+2.6%</font>).</li>  <li>An improved outlook on freight shipping rates is helping to boost sentiment.</li><li>Related ETF: <a href='https://seekingalpha.com/symbol/SEA' title='Invesco Shipping ETF'>SEA</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3253785-morgan-stanley-upgrades-trio-dry-bulk-shippers\" target=\"_blank\">Morgan Stanley upgrades trio of dry bulk shippers</a> (March 28)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3253794-genco-hsipping-and-trading-catches-upgrade\" target=\"_blank\">Genco Shipping &amp; Trading catches an upgrade</a> (March 28)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253892\" data-linked=\"Rally time for shipping stocks\" data-tweet=\"$SBLK $SBLK $SB - Rally time for shipping stocks https://seekingalpha.com/news/3253892-rally-time-for-shipping-stocks?source=tweet\" data-url=\"https://seekingalpha.com/news/3253892-rally-time-for-shipping-stocks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>49&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253886\" data-ts=\"1490710641\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKER\" target=\"_blank\">AKER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253886-u-s-commercialization-of-akers-bios-rapid-cholesterol-self-test-commences-shares-ahead-61\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. commercialization of Akers Bio&#39;s rapid cholesterol self-test commences; shares ahead 61%</a></h4><ul><li>Thinly traded nano cap Akers Biosciences (<a href='https://seekingalpha.com/symbol/AKER' title='Akers Biosciences Inc.'>AKER</a> <font color='green'>+60.7%</font>) jumps on a healthy 28x surge in volume in response to its <a href=\"https://seekingalpha.com/pr/16782467-akers-biosciences-begins-selling-rapid-cholesterol-test-distribution-agreement-first-check\" target=\"_blank\">announcement </a>that exclusive U.S. distributor First Check Diagnostics, LLC has placed an initial order for its Tri-Cholesterol rapid self-test.</li><li>First Check products are sold through major retailers such as CVS, Rite Aid, Target and Kmart.</li><li>Tri-Cholesterol is a disposable screening test that estimates a person's total cholesterol, high density lipoprotein cholesterol and low density lipoprotein cholesterol. It generates a result in five minutes from a finger-stick blood sample.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253886\" data-linked=\"U.S. commercialization of Akers Bio&#39;s rapid cholesterol self-test commences; shares ahead 61%\" data-tweet=\"$AKER - U.S. commercialization of Akers Bio&#39;s rapid cholesterol self-test commences; shares ahead 61% https://seekingalpha.com/news/3253886-u-s-commercialization-of-akers-bios-rapid-cholesterol-self-test-commences-shares-ahead-61?source=tweet\" data-url=\"https://seekingalpha.com/news/3253886-u-s-commercialization-of-akers-bios-rapid-cholesterol-self-test-commences-shares-ahead-61\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253887\" data-ts=\"1490710641\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WWE\" target=\"_blank\">WWE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253887-wwe-stubhub-ink-multi-year-ticket-resale-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WWE, StubHub ink multi-year ticket resale deal</a></h4><ul>   <li>WWE (<a href=\"http://seekingalpha.com/symbol/WWE\" target=\"_blank\">WWE</a> <font color='green'>+2%</font>) has come to a <a href=\"https://seekingalpha.com/pr/16782860-wwe-stubhub-announce-multi-year-agreement\" target=\"_blank\">multi-year deal with StubHub</a>, making the reseller its exclusive ticket resale marketplace in the U.S. and Canada.</li>    <li>It's the first secondary ticket partner for the wrestling league.</li>    <li>The company notes the deal is in place in time for WrestleMania 33 this coming Sunday in Orlando, Fla.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253887\" data-linked=\"WWE, StubHub ink multi-year ticket resale deal\" data-tweet=\"$WWE - WWE, StubHub ink multi-year ticket resale deal https://seekingalpha.com/news/3253887-wwe-stubhub-ink-multi-year-ticket-resale-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3253887-wwe-stubhub-ink-multi-year-ticket-resale-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253881\" data-ts=\"1490709853\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INFO\" target=\"_blank\">INFO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253881-ihs-markit-up-2_9-after-q1-report-shows-revenue-progress\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IHS Markit up 2.9% after Q1 report shows revenue progress</a></h4><ul>   <li>IHS Markit (NASDAQ:<a href='https://seekingalpha.com/symbol/INFO' title='IHS Markit Ltd.'>INFO</a>) has <font color='green'>risen 2.9%</font> in early going after its <a href=\"https://seekingalpha.com/news/3253749-ihs-markit-eps-revenue-line\" target=\"_blank\">fiscal Q1</a>, an in-line report that included new financial-services revenue from the now-merged company.</li>    <li>Revenues were up 54% on an as-reported basis; organic revenue was up 1%, and normalized organic revenue up 2%.</li>    <li>EBITDA came in at $320M, beating an expected $318M. Cash flow from operations was $251M; free cash flow came to $179M.</li>    <li>Revenue by segment: Resources, $196.9M (down 9%); Transportation, $224.9M (up 13%); CMS, $126.5M (down 5%); Financial Services, $295.M (new).</li>    <li>Revenue by type: Recurring fixed, $617.1M (up 39%); Recurring variable, $106.4M (new); non-recurring, $120.7M (up 15%).</li>    <li>For full 2017, the company is guiding to revenue of $3.49B-$3.56B (vs. consensus for $3.53B), adjusted EBITDA of $1.375B-$1.4B (vs. expected $1.385B), and EPS of $2.02-$2.08 (vs. consensus for $2.06).</li>    <li><a href=\"https://seekingalpha.com/pr/16782346-ihs-markit-reports-first-quarter-2017-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3253881\" data-linked=\"IHS Markit up 2.9% after Q1 report shows revenue progress\" data-tweet=\"$INFO - IHS Markit up 2.9% after Q1 report shows revenue progress https://seekingalpha.com/news/3253881-ihs-markit-up-2_9-after-q1-report-shows-revenue-progress?source=tweet\" data-url=\"https://seekingalpha.com/news/3253881-ihs-markit-up-2_9-after-q1-report-shows-revenue-progress\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253877\" data-ts=\"1490709761\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYRX\" target=\"_blank\">CYRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253877-cryoport-prices-stock-offering-2_00-shares-down-44\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cryoport prices stock offering at $2.00; shares down 44%</a></h4><ul><li>Thinly traded nano cap Cryoport (<a href='https://seekingalpha.com/symbol/CYRX' title='CryoPort, Inc.'>CYRX</a> <font color='red'>-43.5%</font>) slumps on a whopping 85x surge in volume in response to the <a href=\"https://seekingalpha.com/pr/16783049-cryoport-announces-pricing-public-offering-common-stock\" target=\"_blank\">pricing </a>of its public offering of 5.5M common shares at $2.00. Underwriters over-allotment is an additional 825K shares. Net proceeds of ~$9.9M will be used for general corporate purposes. Closing date is March 31.</li><li>Yesterday's close was $3.7519.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253877\" data-linked=\"Cryoport prices stock offering at $2.00; shares down 44%\" data-tweet=\"$CYRX - Cryoport prices stock offering at $2.00; shares down 44% https://seekingalpha.com/news/3253877-cryoport-prices-stock-offering-2_00-shares-down-44?source=tweet\" data-url=\"https://seekingalpha.com/news/3253877-cryoport-prices-stock-offering-2_00-shares-down-44\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253869\" data-ts=\"1490709098\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBIO\" target=\"_blank\">CBIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253869-catalyst-bios-next-gen-hemophilia-candidate-cb-2679-isu304-cleared-to-begin-clinical-trials\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Catalyst Bio&#39;s next gen hemophilia candidate CB 2679/ISU304 cleared to begin clinical trials in Korea; shares rocket 158%</a></h4><ul><li>Thinly traded nano cap Catalyst Biosciences (<a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a> <font color='green'>+157.7%</font>) jumps out the blocks this morning on light volume in response to its <a href=\"https://seekingalpha.com/pr/16782671-catalyst-biosciences-announces-ind-approval-south-korea-next-generation-subcutaneous-factor\" target=\"_blank\">announcement </a>that the Korean Ministry of Food and Drug Safety has approved the Investigational New Drug Application &#40;IND&#41; for hemophilia B candidate CB 2679d/ISU304 submitted by collaboration partner <a href=\"http://www.abxis.com/eng/\" target=\"_blank\">ISU Abxis</a>. A Phase 1/2 proof-of-concept study in patients with severe hemophilia B will be initiated next quarter.</li><li><a href=\"http://www.catalystbiosciences.com/pipeline/hemostasis/#ix\" target=\"_blank\">CB 2679d/ISU304</a> is a next-generation coagulation Factor IX variant that has shown a longer duration of action than other Factor IX products in preclinical models. The company says it has potential for subcutaneous prophylactic treatment of hemophilia B instead of the traditional route of IV infusion.</li><li>ISU Abxis has the option for exclusive commercial rights in South Korea. Catalyst retains all rights elsewhere.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253869\" data-linked=\"Catalyst Bio&#39;s next gen hemophilia candidate CB 2679/ISU304 cleared to begin clinical trials in Korea; shares rocket 158%\" data-tweet=\"$CBIO - Catalyst Bio&#39;s next gen hemophilia candidate CB 2679/ISU304 cleared to begin clinical trials in Korea; shares rocket 158% https://seekingalpha.com/news/3253869-catalyst-bios-next-gen-hemophilia-candidate-cb-2679-isu304-cleared-to-begin-clinical-trials?source=tweet\" data-url=\"https://seekingalpha.com/news/3253869-catalyst-bios-next-gen-hemophilia-candidate-cb-2679-isu304-cleared-to-begin-clinical-trials\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253865\" data-ts=\"1490708737\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORIG\" target=\"_blank\">ORIG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253865-ocean-rig-files-for-chapter-15-bankruptcy-protection-sharesminus-60\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ocean Rig files for Chapter 15 bankruptcy protection; shares -60%</a></h4><ul>     <li>Ocean Rig UDW (<a href='https://seekingalpha.com/symbol/ORIG' title='Ocean Rig UDW Inc.'>ORIG</a> <font color='red'>-60.1%</font>) <a href=\"https://seekingalpha.com/pr/16782786-ocean-rig-udw-inc-reaches-agreement-comprehensive-deleveraging-recapitalization-transaction\" target=\"_blank\">files for bankruptcy protection</a> under Chapter 15, the section of the U.S. code dealing with cross-border insolvencies.</li>     <li>The U.S. Bankruptcy Court in New York late yesterday granted ORIG a temporary restraining order to <a href=\"https://www.wsj.com/articles/ocean-rig-udw-files-for-u-s-bankruptcy-protection-1490707211\" target=\"_blank\">block creditors from interfering</a> with its debt restructuring.</li>     <li>ORIG says the U.S. filing was necessary to protect it from &ldquo;vulture investors&rdquo; who bought up the company&rsquo;s debt last year on the cheap, hoping to take advantage of the steep decline in oil prices.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253865\" data-linked=\"Ocean Rig files for Chapter 15 bankruptcy protection; shares -60%\" data-tweet=\"$ORIG - Ocean Rig files for Chapter 15 bankruptcy protection; shares -60% https://seekingalpha.com/news/3253865-ocean-rig-files-for-chapter-15-bankruptcy-protection-sharesminus-60?source=tweet\" data-url=\"https://seekingalpha.com/news/3253865-ocean-rig-files-for-chapter-15-bankruptcy-protection-sharesminus-60\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253853\" data-ts=\"1490707717\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDS\" target=\"_blank\">FDS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253853-factsetminus-3_9-fiscal-q2-revenues-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FactSet -3.9% as fiscal Q2 revenues miss</a></h4><ul>   <li>FactSet Research Systems (NYSE:<a href='https://seekingalpha.com/symbol/FDS' title='FactSet Research Systems Inc.'>FDS</a>) is <font color='red'>down 3.9%</font> premarket after reporting <a href=\"https://seekingalpha.com/news/3253764-factset-research-systems-beats-0_01-misses-revenue\" target=\"_blank\">fiscal Q2 earnings</a> where revenues missed expectations despite a near-5% rise.</li>    <li>Operating income rose 7.5% to $91.7M, while net income fell 1.6% to $66.7M.</li>    <li>Annual Subscription Value rose to $1.19B from a prior-year $1.14B; organic ASV was up 6.5%. Buy-side ASV growth was 6.8%; Sell-side was 4.9%.</li>    <li>Organic revenues were up 7% to $291.5M.</li>    <li>For Q3, it's guiding to GAAP revenues of $301M-$307M (vs. consensus for $301.6M); BISAM is exected to add about $6M. Non-GAAP operating margin is seen at 32-33% (with BISAM contributing a 30-bp reduction), and adjusted EPS is forecast at $1.80-$1.86, vs. consensus for $1.84.</li>    <li><a href=\"http://investor.factset.com/investors/audiocasts\" target=\"_blank\">Conference call</a> to come at 11 a.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16782469-factset-reports-solid-revenue-earnings-growth-second-quarter-2017\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3253853\" data-linked=\"FactSet -3.9% as fiscal Q2 revenues miss\" data-tweet=\"$FDS - FactSet -3.9% as fiscal Q2 revenues miss https://seekingalpha.com/news/3253853-factsetminus-3_9-fiscal-q2-revenues-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3253853-factsetminus-3_9-fiscal-q2-revenues-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253848\" data-ts=\"1490707188\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRSP\" target=\"_blank\">CRSP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253848-crispr-nabs-european-patent-covering-gene-editing-technology-shares-up-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CRISPR nabs European patent covering gene editing technology; shares up 2% premarket</a></h4><ul><li>CRISPR Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CRSP' title='CRISPR Therapeutics'>CRSP</a>) perks up&nbsp;<font color='green'>2%</font>&nbsp;premarket, albeit on only 110 shares, after its <a href=\"https://seekingalpha.com/pr/16782648-crispr-therapeutics-announces-european-patent-crispr-cas-gene-editing\" target=\"_blank\">announcement </a>that the European Patent Office has issued a patent covering its in-licensed gene editing technology, specifically the CRISPR/Cas9 single-guide gene editing system for uses in both non-cellular and cellular settings, including cells from vertebrate animals (eukaryotic) in addition to composition claims for use in any setting, including claims for use in a method of therapeutic treatment of a patient.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253848\" data-linked=\"CRISPR nabs European patent covering gene editing technology; shares up 2% premarket\" data-tweet=\"$CRSP - CRISPR nabs European patent covering gene editing technology; shares up 2% premarket https://seekingalpha.com/news/3253848-crispr-nabs-european-patent-covering-gene-editing-technology-shares-up-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3253848-crispr-nabs-european-patent-covering-gene-editing-technology-shares-up-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253846\" data-ts=\"1490707146\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCL\" target=\"_blank\">CCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253846-carnival-beats-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Carnival beats by $0.03, beats on revenue</a></h4><ul><li>Carnival (NYSE:<a href='https://seekingalpha.com/symbol/CCL' title='Carnival Corporation'>CCL</a>): FQ1 EPS of $0.38 <font color='green'>beats by $0.03</font>.</li><li>Revenue of $3.79B (+3.8% Y/Y) <font color='green'>beats by $10M</font>.</li><li>Shares <font color='green'>+1.34%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/16783002-carnival-corporation-and-plc-reports-first-quarter-earnings\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3253846\" data-linked=\"Carnival beats by $0.03, beats on revenue\" data-tweet=\"$CCL $CUK - Carnival beats by $0.03, beats on revenue https://seekingalpha.com/news/3253846-carnival-beats-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3253846-carnival-beats-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253841\" data-ts=\"1490706975\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253841-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/CYRX' title='CryoPort, Inc.'>CYRX</a> <font color='red'>-45%</font>&nbsp;on initiating equity offering.</li><li><a href='https://seekingalpha.com/symbol/SCON' title='Superconductor Technologies Inc.'>SCON</a> <font color='red'>-16%&nbsp;</font>on Q4 earnings miss.</li><li><a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a> <font color='red'>-16%</font>.</li><li><a href='https://seekingalpha.com/symbol/DGLY' title='Digital Ally, Inc.'>DGLY</a> <font color='red'>-12%</font>&nbsp;on Q4 earnings.</li><li><a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a> <font color='red'>-11%</font>.</li><li><a href='https://seekingalpha.com/symbol/CEMP' title='Cempra, Inc.'>CEMP</a> <font color='red'>-5%</font>&nbsp;on withdrawing marketing application in Europe.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3253841\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$CYRX $SCON $HTGM - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3253841-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3253841-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253842\" data-ts=\"1490706871\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253842-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul> <li><a href='https://seekingalpha.com/symbol/XRA' title='Exeter Resource Corporation'>XRA</a> <font color='green'>+60%</font> on being acquired by Goldcorp for ~$185M.</li><li><a href='https://seekingalpha.com/symbol/AKER' title='Akers Biosciences Inc.'>AKER</a> <font color='green'>+32%</font> on receiving initial order for rapid cholesterol self-test from First Check Diagnostics.</li><li><a href='https://seekingalpha.com/symbol/HPJ' title='Highpower International, Inc.'>HPJ</a> <font color='green'>+15%</font> on Q4 earnings.</li><li><a href='https://seekingalpha.com/symbol/CARA' title='Cara Therapeutics Inc.'>CARA</a> <font color='green'>+13%</font> on successful mid-stage study of  lead candidate I.V. CR845.</li><li><a href='https://seekingalpha.com/symbol/SB' title='Safe Bulkers Inc.'>SB</a> <font color='green'>+11%</font> on upgrade by Morgan Stanley.</li><li><a href='https://seekingalpha.com/symbol/FNJN' title='Finjan Holdings, Inc.'>FNJN</a> <font color='green'>+9%</font> on Q4 earnings.</li><li><a href='https://seekingalpha.com/symbol/EDIT' title='Editas Medicine'>EDIT</a> <font color='green'>+7%</font> on Buy rating.</li><li><a href='https://seekingalpha.com/symbol/TSRO' title='Tesaro'>TSRO</a> <font color='green'>+6%</font> on FDA approval of ZEJULA.</li><li><a href='https://seekingalpha.com/symbol/RHT' title='Red Hat, Inc.'>RHT</a> <font color='green'>+5%</font> on Q4 earnings and better than expected guidance.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3253842\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$XRA $AKER $HPJ - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3253842-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3253842-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253840\" data-ts=\"1490706753\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HPJ\" target=\"_blank\">HPJ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253840-highpower-soars-after-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Highpower soars after Q4 results</a></h4><ul><li>Net income of $1.81M, or $0.12 per diluted share vs. $0.3M, or $0.02 per diluted share, in the prior year period.</li><li>EBITDA of $3.6M, compared to $1.9M in the same quarter a year ago.</li><li>\"We were pleased to deliver exceptional operating results for fiscal 2016. This growth was driven by double digit growth of our lithium battery business,\" said CEO George Pan.</li><li><a href='https://seekingalpha.com/symbol/HPJ' title='Highpower International, Inc.'>HPJ</a> <font color='green'>+14.7%</font> premarket</li><li><a href=\"https://seekingalpha.com/news/3253769-highpower-international-reports-q4-results\" target=\"_blank\">Q4 results </a></li></ul><div class=\"tiny-share-widget\" data-id=\"3253840\" data-linked=\"Highpower soars after Q4 results\" data-tweet=\"$HPJ - Highpower soars after Q4 results https://seekingalpha.com/news/3253840-highpower-soars-after-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3253840-highpower-soars-after-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253838\" data-ts=\"1490706602\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PHIO\" target=\"_blank\">PHIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253838-rxi-pharma-nabs-japanese-patent-covering-lead-product-candidate-rximinus-109-shares-jump-39\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RXi Pharma nabs Japanese patent covering lead product candidate RXI-109; shares jump 39% premarket</a></h4><ul><li>Nano cap RXi Pharmaceuticals (RXII) heads north&nbsp;<font color='green'>39%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16782476-rxi-pharmaceuticals-granted-patent-japan-lead-clinical-candidate-rximinus-109\" target=\"_blank\">announcement </a>that the Japan Patent Office has issued a patent covering lead product candidate RXI-109, specifically composition of matter of sd-rxRNAs targeting connective tissue growth factor for the treatment or prevention of fibrotic disorders, including but not limited to skin fibrosis and proliferative retinopathy.</li><li><a href=\"http://www.rxipharma.com/technology/rxi-109/\" target=\"_blank\">RXI-109</a>, an <a href=\"http://www.rxipharma.com/technology/sd-rxrna/\" target=\"_blank\">sd-rxRNA</a> therapeutic, is in Phase 2 development for the treatment of dermal scarring and Phase 1 for retinal scarring.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253838\" data-linked=\"RXi Pharma nabs Japanese patent covering lead product candidate RXI-109; shares jump 39% premarket\" data-tweet=\"$PHIO - RXi Pharma nabs Japanese patent covering lead product candidate RXI-109; shares jump 39% premarket https://seekingalpha.com/news/3253838-rxi-pharma-nabs-japanese-patent-covering-lead-product-candidate-rximinus-109-shares-jump-39?source=tweet\" data-url=\"https://seekingalpha.com/news/3253838-rxi-pharma-nabs-japanese-patent-covering-lead-product-candidate-rximinus-109-shares-jump-39\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253835\" data-ts=\"1490706396\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253835-facebook-adds-camera-effects-ephemeral-stories-and-direct-sharing-features-to-news-feed\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Facebook adds camera effects, ephemeral stories and direct sharing features to News Feed</a></h4><ul><li>Characteristics highly alike those principally associated with Snapchat and some of which are integrated already in various capacities across Facebook's other products, mask, frame, filter effects, 24-hour stories and direct ephemeral sharing of photos and videos are <a href=\"http://newsroom.fb.com/news/2017/03/more-ways-to-share-with-the-facebook-camera/\" target=\"_blank\">rolling out</a> on Facebook's (NASDAQ:<a href='https://seekingalpha.com/symbol/FB' title='Facebook'>FB</a>) central offering.</li><li>Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>)&nbsp;<font color='red'>-3.65%</font>&nbsp;at $22.96 pre-market.</li><li><a href=\"https://www.facebook.com/facebook/videos/10155654381926729/\" target=\"_blank\">Video</a> [Facebook]</li></ul><div class=\"tiny-share-widget\" data-id=\"3253835\" data-linked=\"Facebook adds camera effects, ephemeral stories and direct sharing features to News Feed\" data-tweet=\"$FB $FB $SNAP - Facebook adds camera effects, ephemeral stories and direct sharing features to News Feed https://seekingalpha.com/news/3253835-facebook-adds-camera-effects-ephemeral-stories-and-direct-sharing-features-to-news-feed?source=tweet\" data-url=\"https://seekingalpha.com/news/3253835-facebook-adds-camera-effects-ephemeral-stories-and-direct-sharing-features-to-news-feed\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253821\" data-ts=\"1490704963\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GG\" target=\"_blank\">GG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253821-goldcorp-to-team-barrick-to-consolidate-cerro-casale-caspiche-projects\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldcorp to team with Barrick to consolidate Cerro Casale, Caspiche projects</a></h4><ul>     <li>Goldcorp (NYSE:<a href='https://seekingalpha.com/symbol/GG' title='Goldcorp Inc.'>GG</a>) and Barrick Gold (ABX) say they are <a href=\"https://seekingalpha.com/pr/16782533-goldcorp-barrick-consolidate-cerro-casale-caspiche-gold-projects-50-50-joint-venture\" target=\"_blank\">forming a 50-50 joint venture</a> to study building gold mines in Chile's Maricunga belt, including the Cerro Casale project, which is one of the world's biggest undeveloped gold deposits.</li>     <li>In a <a href=\"http://www.reuters.com/article/us-goldcorp-barrick-gold-chile-idUSKBN16Z1FY\" target=\"_blank\">series of deals costing GG ~$445M upfront</a> in cash and shares, the miner <a href=\"https://seekingalpha.com/pr/16782532-kinross-announces-sale-cerro-casale-interest\" target=\"_blank\">agrees to acquire</a> Kinross Gold's (NYSE:<a href='https://seekingalpha.com/symbol/KGC' title='Kinross Gold Corporation'>KGC</a>) 25% stake in Cerro Casale and all of its Quebrada Seca exploration project for an initial $260M in cash.</li>     <li>GG also <a href=\"https://seekingalpha.com/pr/16782534-goldcorp-acquire-exeter-resource-corporation\" target=\"_blank\">agrees to buy</a> junior miner Exeter Resource (NYSEMKT:<a href='https://seekingalpha.com/symbol/XRA' title='Exeter Resource Corporation'>XRA</a>) and its Caspiche project, located just six miles from Cerro Casale, for ~$185M in shares.</li>     <li>Finally, GG also will buy a 25% stake in Cerro Casale from ABX, reducing ABX's holding in the project to 50% from 75%; GG will pay for the stake by funding all initial expenditures on Cerro Casale and by contributing the Caspiche project into the joint venture.</li>     <li>Cerro Casale contains proven and probable reserves of 23.2M oz. of gold, 58.7M oz. of silver and 5.8B lbs. of copper.</li><li>XRA&nbsp;<font color='green'>+57.7%</font>, KGC <font color='green'>+4.6%</font>, ABX <font color='red'>-0.1%</font>, GG <font color='red'>-1.5%</font> premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253821\" data-linked=\"Goldcorp to team with Barrick to consolidate Cerro Casale, Caspiche projects\" data-tweet=\"$GG $GG $GOLD - Goldcorp to team with Barrick to consolidate Cerro Casale, Caspiche projects https://seekingalpha.com/news/3253821-goldcorp-to-team-barrick-to-consolidate-cerro-casale-caspiche-projects?source=tweet\" data-url=\"https://seekingalpha.com/news/3253821-goldcorp-to-team-barrick-to-consolidate-cerro-casale-caspiche-projects\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253817\" data-ts=\"1490704557\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EDIT\" target=\"_blank\">EDIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253817-crispr-cas9-gene-editing-firms-perk-up-premarket-after-bullish-ratings-from-chardan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CRISPR/Cas9 gene editing firms perk up premarket after bullish ratings from Chardan</a></h4><ul><li>Chardan Capital is bullish on CRISPR/Cas9 gene editing players Editas Medicine (NASDAQ:<a href='https://seekingalpha.com/symbol/EDIT' title='Editas Medicine'>EDIT</a>), CRISPR Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CRSP' title='CRISPR Therapeutics'>CRSP</a>) and Intellia Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NTLA' title='Intellia Therapeutics'>NTLA</a>), rating all Buys with implied upsides ranging from 29% to 214%.</li><li>EDIT is up&nbsp;<font color='green'>7%</font>&nbsp;premarket and CRSP&nbsp;<font color='green'>3%</font>, both on light volume. No pre-session trading has been reported for NTLA.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253817\" data-linked=\"CRISPR/Cas9 gene editing firms perk up premarket after bullish ratings from Chardan\" data-tweet=\"$EDIT $EDIT $CRSP - CRISPR/Cas9 gene editing firms perk up premarket after bullish ratings from Chardan https://seekingalpha.com/news/3253817-crispr-cas9-gene-editing-firms-perk-up-premarket-after-bullish-ratings-from-chardan?source=tweet\" data-url=\"https://seekingalpha.com/news/3253817-crispr-cas9-gene-editing-firms-perk-up-premarket-after-bullish-ratings-from-chardan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253808\" data-ts=\"1490704132\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CALA\" target=\"_blank\">CALA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253808-calithera-entitled-to-12m-milestone-from-incyte-based-on-early-stage-progress-cbminus-1158\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Calithera entitled to $12M milestone from Incyte based on early-stage progress with CB-1158; shares up 5% premarket</a></h4><ul><li>Calithera Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/CALA' title='Calithera Biosciences'>CALA</a>) perks up&nbsp;<font color='green'>5%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16782448-calithera-receive-12-million-milestone-payment-incyte-achievement-pharmacokinetic\" target=\"_blank\">announcement </a>that it has earned a $12M milestone payment from collaboration partner Incyte (NASDAQ:<a href='https://seekingalpha.com/symbol/INCY' title='Incyte Corporation'>INCY</a>) triggered by the achievement of pharmacokinetic and pharmacodynamic goals for oncology candidate CB-1158.</li><li>CB-1158 inhibits an enzyme called arginase that is found in myeloid-derived suppressor cells which plays a key role in suppressing the immune system's anti-tumor activity. Specifically, it depletes the amino acid arginine in the tumor microenvironment and prevents the activation of the immune system's cytotoxic T cells and NK (natural killer) cells.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3238622-cithera-bio-35-percent-premarket-partnership-incyte-develop-cbminus-1158\" target=\"_blank\">Cithera Bio up 35% premarket on partnership with Incyte to develop CB-1158</a> (Jan. 30)</li></ul><div class=\"tiny-share-widget\" data-id=\"3253808\" data-linked=\"Calithera entitled to $12M milestone from Incyte based on early-stage progress with CB-1158; shares up 5% premarket\" data-tweet=\"$CALA $CALA $INCY - Calithera entitled to $12M milestone from Incyte based on early-stage progress with CB-1158; shares up 5% premarket https://seekingalpha.com/news/3253808-calithera-entitled-to-12m-milestone-from-incyte-based-on-early-stage-progress-cbminus-1158?source=tweet\" data-url=\"https://seekingalpha.com/news/3253808-calithera-entitled-to-12m-milestone-from-incyte-based-on-early-stage-progress-cbminus-1158\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253802\" data-ts=\"1490703614\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CARA\" target=\"_blank\">CARA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253802-caras-lead-product-candidate-successful-in-mid-stage-study-shares-ahead-15-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cara&#39;s lead product candidate successful in mid-stage study; shares ahead 15% premarket</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/16782445-cara-therapeutics-announces-positive-top-line-data-part-phase-2-3-trial-v-cr845-chronic\" target=\"_blank\">Results </a>from Part A of a Phase 2/3 clinical trial assessing Cara Therapeutics' (NASDAQ:<a href='https://seekingalpha.com/symbol/CARA' title='Cara Therapeutics Inc.'>CARA</a>) lead product candidate I.V. CR845 in patients with uremic pruritus &#40;UP&#41; met both primary and secondary endpoints.</li><li>The primary endpoint was the change from baseline in mean worst itching score at week 8 as measured by a 0 -10 Numeric Rating Scale &#40;NRS&#41;. Patients receiving I.V. CR845 showed a 68% reduction compared to placebo (p&lt;0.0019).</li><li>The secondary endpoint assessed quality-of-life metrics using a scale called Skindex-10 score. Patients in the treatment group experienced a 100% greater reduction from baseline in average Skindex-10 score compared to placebo (p&lt;0.0007).</li><li>I.V. CR845 was well-tolerated over the eight-week treatment period with no new safety signals observed. The most common adverse events were transient paresthesia (mid-facial tingling or numbness) and dizziness.</li><li>The company plans to schedule an end-of-Phase 2 meeting with the FDA to review the results and determine the optimal dose for the Phase 3 and define the path to approval. The Phase 3 protocol will assess I.V. 845 administered 3x/week after dialysis over a 12-week treatment period in up to 240 patients with moderate-to-severe UP.</li><li>Management will host a conference call this morning at 8:30 am ET to discuss the data.</li><li>Shares are up&nbsp;<font color='green'>15%</font>&nbsp;premarket on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253802\" data-linked=\"Cara&#39;s lead product candidate successful in mid-stage study; shares ahead 15% premarket\" data-tweet=\"$CARA - Cara&#39;s lead product candidate successful in mid-stage study; shares ahead 15% premarket https://seekingalpha.com/news/3253802-caras-lead-product-candidate-successful-in-mid-stage-study-shares-ahead-15-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3253802-caras-lead-product-candidate-successful-in-mid-stage-study-shares-ahead-15-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253789\" data-ts=\"1490702572\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CEMP\" target=\"_blank\">CEMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253789-cempra-withdraws-solithromycin-marketing-application-in-europe-shares-down-6-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cempra withdraws solithromycin marketing application in Europe; shares down 6% premarket</a></h4><ul><li>Cempra (NASDAQ:<a href='https://seekingalpha.com/symbol/CEMP' title='Cempra, Inc.'>CEMP</a>) eases&nbsp;<font color='red'>6%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16782460-cempra-withdraws-solithromycin-marketing-authorization-application-europe\" target=\"_blank\">announcement </a>that it has withdrawn its Marketing Authorization Application &#40;MAA&#41; from the European Medicines Agency &#40;EMA&#41; seeking approval of oral capsule and IV formulations of solithromycin for the treatment of community-acquired pneumonia in adults.</li><li>The company took action after receiving the Day 120 list of questions from the advisory committee CHMP that implied that additional data would be required for a positive opinion backing approval. It says the withdrawal will save considerable resources while it aligns its plan to provide the data to both the EMA and FDA.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253789\" data-linked=\"Cempra withdraws solithromycin marketing application in Europe; shares down 6% premarket\" data-tweet=\"$CEMP - Cempra withdraws solithromycin marketing application in Europe; shares down 6% premarket https://seekingalpha.com/news/3253789-cempra-withdraws-solithromycin-marketing-application-in-europe-shares-down-6-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3253789-cempra-withdraws-solithromycin-marketing-application-in-europe-shares-down-6-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>150&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253775\" data-ts=\"1490700447\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TCEHY\" target=\"_blank\">TCEHY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253775-tencent-discloses-5-stake-in-tesla\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tencent discloses 5% stake in Tesla</a></h4><ul> <li>Tencent Holdings (<a href='https://seekingalpha.com/symbol/TCEHY' title='Tencent Holding Ltd. ADR'>OTCPK:TCEHY</a>) reports holding a 5% passive stake in Tesla (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>).</li> <li>Tencent is a Chinese conglomerate with interests in tech, media and consumer services.</li> <li><a href=\"https://seekingalpha.com/filing/3476480\" target=\"_blank\">SEC Form 13G</a></li><li>Shares of Tesla are <font color='green'>up 2.97%</font> premarket to $278.25.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3253775\" data-linked=\"Tencent discloses 5% stake in Tesla\" data-tweet=\"$TCEHY $TCEHY $TSLA - Tencent discloses 5% stake in Tesla https://seekingalpha.com/news/3253775-tencent-discloses-5-stake-in-tesla?source=tweet\" data-url=\"https://seekingalpha.com/news/3253775-tencent-discloses-5-stake-in-tesla\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>128&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253770\" data-ts=\"1490699373\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DECK\" target=\"_blank\">DECK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253770-red-mountain-ratchets-up-pressure-on-deckers-outdoor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Red Mountain ratchets up pressure on Deckers Outdoor</a></h4><ul> <li>Red Mountain Capital Partners calls on Deckers Outdoor (NASDAQ:<a href='https://seekingalpha.com/symbol/DECK' title='Deckers Outdoor Corporation'>DECK</a>) to rationalize its retail store network.</li><li>The firm also wants the retailer to streamline its brand portfolio, cut costs and optimize its balance sheet among other measures.</li><li>Red Mountain is also calling on the Deckers board to explore a sale of the company.</li><li>Red Mountain holds a stake in Deckers of 3.3%.</li><li>DECK&nbsp;<font color='green'>+1.75%</font>&nbsp;premarket to $57.50. Shares trade 17% below their 52-week high.</li>  <li>Source: <a href=\"https://seekingalpha.com/pr/16782039-red-mountain-calls-board-deckers-outdoor-corporation-explore-sale-company\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3253770\" data-linked=\"Red Mountain ratchets up pressure on Deckers Outdoor\" data-tweet=\"$DECK - Red Mountain ratchets up pressure on Deckers Outdoor https://seekingalpha.com/news/3253770-red-mountain-ratchets-up-pressure-on-deckers-outdoor?source=tweet\" data-url=\"https://seekingalpha.com/news/3253770-red-mountain-ratchets-up-pressure-on-deckers-outdoor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253766\" data-ts=\"1490699028\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTN\" target=\"_blank\">NTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253766-ntn-buzztime-announces-direct-offering-of-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NTN Buzztime announces direct offering of shares</a></h4><ul> <li>NTN Buzztime (NYSEMKT:<a href='https://seekingalpha.com/symbol/NTN' title='NTN Buzztime, Inc'>NTN</a>) enters a subscription agreement with certain investors to sell up to 200K shares of stock at $7.85 per share.</li><li>The proceeds to NTN from the offering is expected to be approximately $1.546M after deducting estimated offering expenses.</li><li>The offering is expected to close on or about March 31.</li>                 <li>The company says it will use the proceeds for general corporate purposes, which may include working capital, general and administrative expenses, capital expenditures and implementation of its strategic priorities.</li>  <li>NTN  <font color='red'>-2.09%</font>&nbsp;premarket to  $7.56.</li>  <li>Source: <a href=\"https://seekingalpha.com/pr/16782043-ntn-buzztime-announces-registered-direct-offering-common-stock\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3253766\" data-linked=\"NTN Buzztime announces direct offering of shares\" data-tweet=\"$NTN - NTN Buzztime announces direct offering of shares https://seekingalpha.com/news/3253766-ntn-buzztime-announces-direct-offering-of-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3253766-ntn-buzztime-announces-direct-offering-of-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253759\" data-ts=\"1490698629\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MKC\" target=\"_blank\">MKC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253759-on-mccormicks-q1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on McCormick&#39;s Q1</a></h4><ul>     <li>McCormick (NYSE:<a href='https://seekingalpha.com/symbol/MKC' title='McCormick & Company, Inc.'>MKC</a>)&nbsp;reports sales rose 4% on a constant currency basis in <a href=\"https://seekingalpha.com/pr/16782389-mccormick-reports-first-quarter-results-latest-financial-outlook\" target=\"_blank\">Q1</a>.</li>     <li>Acquisition contributed 3 percentage point of growth in the quarter.</li>     <li>Segment revenue: Consumer: $638.6M (+1%, +2% on a constant currency basis); Industrial: $405.1M (+2%, +6% on a&nbsp;constant currency basis).</li>     <li>Gross margin rate improved 30 bps to 39.6%.</li>     <li>Segment operating income: Consumer: $97.9M (+4%); Industrial: $39.9M (+10%).</li>     <li>Adjusted operating margin rate grew 50 bps to 13.2%.</li>     <li>Income from unconsolidated operations decreased 16.7% to $7M.</li>     <li><b>FY2017 Guidance</b>:&nbsp;Sales: &nbsp;+3% to +5% (+5% to +7% in constant currency); Operating income: +9% to +11%; Adjusted operating income: +8% to +10%; Diluted EPS: $3.98 to $4.06; Adjusted diluted EPS: $4.05 to $4.13.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3253759\" data-linked=\"More on McCormick&#39;s Q1\" data-tweet=\"$MKC - More on McCormick&#39;s Q1 https://seekingalpha.com/news/3253759-on-mccormicks-q1?source=tweet\" data-url=\"https://seekingalpha.com/news/3253759-on-mccormicks-q1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253758\" data-ts=\"1490698393\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVEO\" target=\"_blank\">AVEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253758-aveo-pharma-readies-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AVEO Pharma readies equity offering</a></h4><ul><li>AVEO Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AVEO' title='AVEO Pharmaceuticals, Inc.'>AVEO</a>) <a href=\"https://seekingalpha.com/pr/16782394-aveo-announces-proposed-offering-common-stock\" target=\"_blank\">initiates </a>a public offering of common stock. Price, volume and terms have yet to be announced. Net proceeds will fund working capital and general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253758\" data-linked=\"AVEO Pharma readies equity offering\" data-tweet=\"$AVEO - AVEO Pharma readies equity offering https://seekingalpha.com/news/3253758-aveo-pharma-readies-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3253758-aveo-pharma-readies-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3253757\" data-ts=\"1490698221\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EVH\" target=\"_blank\">EVH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3253757-evolent-health-prices-equity-offering-market-shares-ease-5-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Evolent Health prices equity offering at market; shares ease 5% premarket</a></h4><ul><li>Evolent Health (NYSE:<a href='https://seekingalpha.com/symbol/EVH' title='Evolent Health'>EVH</a>) <a href=\"https://seekingalpha.com/pr/16782255-evolent-health-inc-announces-pricing-secondary-public-offering-class-common-stock\" target=\"_blank\">prices </a>its secondary public offering of 7.5M shares of common stock at market. Underwriters over-allotment is an additional 1.125M shares. Closing date is March 31.</li><li>All shares are being offering by existing shareholders. The last reported sale yesterday was at $21.25.</li><li>Shares are down&nbsp;<font color='red'>5%</font>&nbsp;premarket but only on 100 shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3253757\" data-linked=\"Evolent Health prices equity offering at market; shares ease 5% premarket\" data-tweet=\"$EVH - Evolent Health prices equity offering at market; shares ease 5% premarket https://seekingalpha.com/news/3253757-evolent-health-prices-equity-offering-market-shares-ease-5-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3253757-evolent-health-prices-equity-offering-market-shares-ease-5-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:50 AM </div></div></li>","count":65,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}